Statin Prescribing Guide.

ISBN:

9780199780129

Title:

Author:

Baliga, Ragavendra R.

Personal Author:

Baliga, Ragavendra R.

Physical Description:

1 online resource (82 pages)

Series:

Oxford American Pocket Notes

Contents:

Intro -- Table of Contents -- 1. Introduction -- 2. History -- 3. Fredrickson Classification of Hyperlipoproteinemias -- 4. Risk Assessment and the NCEP/ATP-III Nine-Step Approach to Dyslipidemia -- Steps 1 to 9 -- 5. Statins - Mechanism of Action -- Additional effects -- 6. Pharmacokinetic Properties -- 7. Dyslipidemia, Statins, and Cardiovascular Risk -- LDL-C -- Non-HDLC -- HDL-C -- Serum triglycerides -- C-reactive protein -- 8. Intensive Versus Standard Statin Therapy -- 9. Complications, Contraindications, and Side Effects -- Liver enzymes -- Managing transaminases -- Muscle problems -- Managing myopathy -- Detecting myopathy -- Fetal effects -- Renal failure -- 10. Drug Interactions -- 11. Statin Dosage and Administration Guidelines -- Lovastatin (Altocor®, Mevacor®) -- Pravastatin (Pravachol®) -- Simvastatin (Zocor®) -- Fluvastatin (Lescol®, Lescol XL®) -- Atorvastatin (Lipitor®) -- Rosuvastatin (Crestor®) -- Pitavastatin (Livalo®) -- 12. Special Groups -- Women -- Elderly -- Diabetics -- Stroke -- Aortic stenosis -- 13. Drug Combinations -- Statin and bile acid sequestrants (BAS) -- Simvastatin with ezetimibe (Vytorin®) -- Statins and niacin -- Statins and fibrates -- Statins and omega-3 fatty acids -- 14. Final Conclusions -- 15. References -- 16. Appendix.

Local Note:

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2022. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

Subject Term:

Tourism -- Management.

Hotel management.

Format:

Electronic Resources

Electronic Access:

Click here to view book

Publication Date:

2010

Publication Information:

Cary :

Oxford University Press, Incorporated,

2010.

Available:*

Shelf Number	Material Type	Copy	Shelf Location	Status
616.3997	1:E-BOOK	1	1:ON-DEMAND	Searching... Unknown

Bound With These Titles

On Order

Summary

The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere. As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. As a class, they are well-tolerated by most patients and are easy to administer. However, the withdrawal of cerivastatin (Baycol) from the market in 2001 due to severe myopathy in some patients, has led to increased concern among clinicians with respect to this and other side effects, such as liver and kidney disease. Some studies suggest that this has led to increased reluctance among clinicians to initiate a statin drug regimen or to adjust dosage to increase therapeutic effect. While a small minority of patients do develop serious complications while on statin therapy, current clinical evidence strongly suggests that the benefits of timely statin administration significantly outweigh the risks. Oxford American Pocket Notes: Statin Prescribing Guide aims to provide clinicians with concise, easily accessible guidance on prescribing statins in various clinical settings. This volume features evidence-based discussion on the indications, pharmacokinetics and safety profiles of the available statins and how these properties translate into selection of the appropriate treatment regimen for the individual patient. Useful tools, such as treatment algorithms, charts, tables and illustrations greatly help enhance the value of this volume as a portable reference tool.